Loading...
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is a Healthcare company (Biotechnology) with a market capitalization of $17.0B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Neurocrine Biosciences, Inc. had a Maz Rating of 4.92 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Profitability (4.96), among the strongest in its sector; its weakest was Valuation (2.46), more expensive than most of its sector. The other factors: Growth 4.79 (among the strongest in its sector); Financial Health 4.35 (above most of its sector); Momentum 3.85 (above most of its sector). The current rating is for members: log in to see it.
At $166.79, Neurocrine Biosciences, Inc. trades at 20.9x trailing earnings, 4.0x sales and 3.8x book value, with an EV/EBITDA of 15.3. Over the last twelve months it generated about $4.2B of revenue and $813M of net income. It runs a gross margin of 97.8%, an operating margin of 23.8% and a net margin of 19.0%. It shows return on equity of 19.7%, return on invested capital of 14.3% and a free cash flow yield of 7.0%. On the balance sheet: a debt-to-equity ratio of 0.10 and a current ratio of 2.04. Over the past 52 weeks the share price ranged from $122.14 to $186.12, with a beta of 0.36.
Neurocrine Biosciences, Inc. does not currently pay a dividend.
37 Wall Street analyst ratings cover the stock: 32 Buy and 5 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.